A Phase 1/2 interventional study of EscharEx 5% (EX-02 formulation) in Superficial Basal Cell Carcinoma and Nodular Basal Cell Carcinoma, sponsored by MediWound Ltd. Status unknown at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-15.
Sponsored by MediWound Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 80th largest by planned enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2021, is one of 12 in phase 1/2, and was the 124th registered.
389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.
Browse Carcinoma, Basal Cell studies →23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
Philogen S.p.A. · Sites in United States, Germany, Greece and 2 more countries
Ages 18+
University of Rochester · Sites in United States
University of Rochester · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 52 Carcinoma, Basal Cell studies recruiting now, 48 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 58 · Phase 3 7 · Phase 4 5
First in 1977; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 50 across 272 interventional studies indexed under Carcinoma, Basal Cell.
Median enrollment 40 across the 139 interventional studies, 80 across the 26 observational. Of the 119 that completed or were terminated, 48 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 171 have an industry lead sponsor. The 10 most frequent:
MediWound Ltd is the lead sponsor of 15 studies on the registry; 3 are open to participants now.
MediWound Ltd has 1 study filed under Carcinoma, Basal Cell — fewer than ten, so there is no comparison to draw.
19 of the studies in Carcinoma, Basal Cell with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06608511University of Wisconsin, MadisonLiquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers | 2026-12 |
| NCT06623201Nathalie ZeitouniBlue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas | 2026-12-01 |
| NCT04616248University of Southern CaliforniaIn Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | 2027-01-09 |
| NCT06384924Tiezhi ZhangRaman Spectroscopy and Skin Cancer | 2027-02-13 |
| NCT05294120Memorial Sloan Kettering Cancer CenterA Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma | 2027-03 |
Add all 19 to your calendar (.ics) → With an account.
Among the 171 studies in Carcinoma, Basal Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be a multicenter, prospective, open label, one-arm study intended to assess the Safety and Efficacy of EscharEx (EX-02) in the treatment of Basal Cell Carcinoma.
In patients with one primary superficial or nodular basal cell carcinoma lesion with a diameter of 5-10mm (Histologically confirmed BCC) located on the trunk or upper extremities (not including the hands), with well-defined borders and no previous radiation therapy.
32 patients are planned to be enrolled into the study from 2-4 US sites. This study will be an Open-Label Study where all patients will be treated with the investigational product EX-02.
Enrollment will be conducted in 2 stages. In the first stage, a group of sixteen (16) patients will be enrolled and treated as detailed below for group 1. Safety results from the first group of patients will be evaluated by the sponsor and by the DSMB. Based on the safety results and DSMB recommendations, the second group of patients will include additional 16 patients that will be enrolled and treated, as detailed below for group 2. All patients will undergo complete surgical excision at the end of the 8 weeks post treatment period and will be followed up until complete clearance is confirmed by biopsy and the wound is closed.
Each patient will go through the following periods during the trial:
Screening and enrollment period (up to 2 weeks, visit#1):
Screening and enrollment duration will be up to 2 weeks and will include the following:
signing informed consent, recording demographics, medical history and concomitant medications, vital signs, physical examination, lesion photography and assessments, and shave biopsy. Only patients with histologically confirmed BCC can be enrolled and start treatment.
Treatment Period (1-3 weeks, 10-14 visits- visits#2-15)
Group 1: 16 patients- 8 patients with superficial BCC and 8 patients with nodular BCC will undergo 7 treatment applications, once every other day (2 weeks).
Group 2: Based on safety results of stage 1 and following DSMB review and recommendations, 16 additional patients (8 patient with superficial BCC and 8 patients with nodular BCC) will undergo 7 daily applications. In case of tolerability issues a rescue therapy of either 7 applications every other day (same as in group 1) or 1 day of drug holiday after which daily treatment will continue, will be allowed as needed.
In both groups, EX-02 5% will be topically applied on the lesion's surface including a margin of 5-10mm, for 8-12 hours each application. All pre application assessments and applications s will be performed at the clinic. Dressing removal will be completed by the patient (by a family member/caregiver) at the patient's home. Between applications, the lesion will be covered by hydrocolloid dressing (applied by the patient or by a family member/caregiver). The treatment area including the skin around the lesion will be photographed before each application at the clinic and assessment of AEs will be performed by the investigator before application and post dressing removal.
This period will include 10 on-site visits, 7 visits for pre application assessments and drug application (visits# 2, 4, 6, 8,10, 12, 14) and 3 on-site visits for post dressing removal and assessments. The following three (3) post dressing removal visits will be performed at the clinic: after first application (post dressing removal) (visit#3), after second application (post dressing removal) (visit#5) and after last application (post dressing removal) (Visit#15). Additional 4 visits post dressing removal (visits#7, 9, 11 and 13) are optional and will be completed only if needed per PI discretion. These optional visits, if performed, can be performed either at the clinic or remotely (by an IRB approved HIPAA compliance telecommunication). Local lab tests will be obtained on visits#1(screening) and visit#15.
Post Treatment period (8 weeks, 4 bi-weekly remote or on site visits, visit#16-19):
Post completion of treatment course, the raw bed and the surrounding skin will be treated toward healing of the skin by Vaseline petrolatum or Aquaphor. Once in 2 weeks the treated area will be photographed, the healing status of the wound and adverse events will be assessed. Assessments on first 3 bi-weekly visits, visit#16- 18 will be performed either on site or remotely (via IRB approved, HIPAA compliance telecommunication), based on physician discretion. The 4th bi-weekly visit i.e. Visit #19 will be performed on site. At the end of the 8 weeks post treatment period, on the 4th bi-weekly visit (visit#19), all patients will undergo complete excision, including a lesion margin of 4-5 mm. The specimen will be sent to dermapathologist for histological clearance examination.
During the follow up stage, patients will be followed and treated with standard of care. Follow up visit # 20 will be performed once biopsy results are available (from the excision performed on visit#19). Results will be recorded in the eCRF. In cases that margins are not clear, patients will undergo additional excisional procedure per standard of care. Histological results from any additional procedure will be recorded. In cases that margin are clear but additional procedure for wound closure is required, the procedure will be recorded. AEs will be monitored until complete clearance of margins is histologically confirmed and until wound is assessed as closed (and sutured were removed).
The total duration of the study for each participating subject is approximately 14-17 weeks: Screening periods (1-2 weeks) + Treatment (1-3 weeks) + Follow up post treatment and histopathology 8 weeks post treatment + Follow up post-surgical excision (approximately 4 weeks- until wound closure).
Inclusion Criteria:
Inclusion Criteria- Patient level
Exclusion Criteria:
Exclusion Criteria- Patient level
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The powder of EX-02 (4 g per vial) should be reconstituted with 10 ml water for injection (WFI) to obtain 5% EX-02 gel. The EX-02 powder and the WFI are to be mixed up to 15 min prior to use. EX-02 5% gel will be topically applied in a thick layer of 2-3 mm on the lesion surface including margin of 5-10 mm for 8-12 hours (preferable over-night) and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
Drug: EscharEx 5% (EX-02 formulation)
EX-02 5% will be topically applied in a thick layer of 2-3 mm on the lesion surface for 8-12 hours including 5-10 mm margins and covered with an occlusive dressing. A new vial should be used for each application. Each patient will be treated with 7 applications.
Also known as: EX-02 5%
Incidence and severity of treatment-emergent AEs (TEAEs) and serious TEAEs (STEAEs).
All adverse events (AEs) will be listed. Adverse events records will include notification whether the AE is local and occurs near or in the target lesion. The AEs will be listed as counts and percentages by System Organ Class (SOC), Preferred Term (PT), severity, and time of onset. Serious Adverse Events will be analyzed in the same way as AEs
Time frame: Through study completion - an average of 16 weeks
Vital signs - proportion of patients with abnormal clinical significant measurements
Assessed pre 2nd, pre 5th application and post last application
Time frame: Up to completion of treatment period - up to 5 weeks
Pain assessments- Proportion of patients with clinical significant elevation in NPRS score
Assesed pre 2nd, pre 5th application and post last application compared with pre 1st application
Time frame: Up to completion of treatment period - up to 5 weeks
Proportion of subjects discontinuing a treatment due to TEAEs, assessed over the entire course of the treatment.
This proportion will be calculated, together with its 95% confidence interval based on the binomial distribution.
Time frame: Up to completion of treatment period - up to 5 weeks
Proportion of subjects that requested to discontinue the treatment
This will be assessed over the entire course of the treatment and will be calculated, together with its 95% confidence interval based on the binomial distribution
Time frame: Up to completion of treatment period - up to 5 weeks
Proportion of patients who reached complete histological clearance at the end of the post treatment period.
biopsy will be taken 8 weeks post completion of treatment. The proportion of patients who reached complete histological clearance at the end of the post treatment period, together with its 95% confidence interval based on the binomial distribution.
Time frame: Up to 13 weeks
Proportion of patients who reached complete clearance at the end of the post treatment period, as clinically assessed prior to surgical removal.
The proportion of patients who reached complete histological clearance as assessed by the investigator at the end of the post treatment period, prior to the excisional biopsy, together with its 95% confidence interval based on the binomial distribution.
Time frame: Up to 13 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2021 (actual). Primary completion is estimated for May 2022, 11 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stem bromelain
MediWound Ltd